See more : Huisen Household International Group Limited (2127.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Monopar Therapeutics Inc. (MNPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monopar Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TASCO Bhd (5140.KL) Income Statement Analysis – Financial Results
- ShineMore Technology Materials Co., Ltd. (8291.TWO) Income Statement Analysis – Financial Results
- North Bud Farms Inc. (NOBDF) Income Statement Analysis – Financial Results
- GET Holdings Limited (8100.HK) Income Statement Analysis – Financial Results
- Nikola Corporation (NKLA) Income Statement Analysis – Financial Results
Monopar Therapeutics Inc. (MNPR)
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.60M | 7.59M | 6.49M | 4.07M | 1.97M | 1.77M | 15.44M | 280.36K | 101.49K |
| General & Administrative | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| Selling & Marketing | -3.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.50M | 0.00 | 0.00 |
| Operating Expenses | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.40M | 16.60M | 1.19M | 688.56K |
| Cost & Expenses | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.40M | 16.60M | 1.19M | 688.56K |
| Interest Income | 429.04M | 21.24K | 24.02K | 81.90K | 98.89K | 103.22K | 48.26K | 7.23K | 1.25K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.22K | 48.26K | 7.23K | 0.00 |
| Depreciation & Amortization | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.33M | 2.10M | 1.19M | 688.56K |
| EBITDA | 429.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -16.55M | 8.03K | 1.25K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.83M | -10.54M | -9.13M | -6.51M | -4.32M | -3.40M | -16.60M | -1.19M | -688.56K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 429.04K | 21.24K | 24.02K | 204.30K | 98.89K | 31.15K | 48.26K | 8.03K | 1.25K |
| Income Before Tax | -8.40M | -10.52M | -9.10M | -6.30M | -4.22M | -3.30M | -16.55M | -1.19M | -687.31K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -21.24K | -24.02K | -81.90K | -98.89K | -71.62K | -2.10M | 800.00 | -688.56K |
| Net Income | -8.40M | -10.49M | -9.08M | -6.22M | -4.13M | -3.23M | -16.55M | -1.19M | -687.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 | -1.59 | -0.11 | -0.06 |
| EPS Diluted | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 | -1.59 | -0.11 | -0.06 |
| Weighted Avg Shares Out | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 10.42M | 10.59M |
| Weighted Avg Shares Out (Dil) | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 10.42M | 10.59M |
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
Why Monopar Therapeutics And EyePoint Pharma Are Trading Higher Today
MNPR Stock Price Increases Over 100% Pre-Market: Why It Happened
Monopar Therapeutics (MNPR) Jumps: Stock Rises 7.4%
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®
Source: https://incomestatements.info
Category: Stock Reports